Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Demonstrate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered as Intravenous Infusion and Subcutaneous Injection in Japanese Healthy Volunteers
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Japanese healthy male subjects age 20 to 45 years of age, and in good health
At screening and baseline, the subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis.
Body mass index within the range of 18 to 28 kg/m2 and weigh 50 to 100 kg
Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to dosing. Acetaminophen is acceptable. Treatment of any biologics within three months prior to dosing. Having live vaccinations within six months prior to dosing.
Participation in any clinical investigation within 4 months prior to dosing.
Donation or loss of 400 mL or more of blood within 3 months; donation or loss of 200 mL or more of blood within 1 month; or donation of component blood within 2 weeks prior to participation.
Significant illness (sinusitis, pneumonia, cystitis, sepsis, etc) within two weeks prior to dosing.
A past personal or close family medical history of cardiac disorders
low blood pressure when standing,
abnormal heart rhythms
acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
Clinically significant drug allergy or history and complication of atopic allergy (asthma, urticaria, eczematous dermatitis)
Known hypersensitivity to the study drug or similar drugs
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or jeopardize participation in the study.
History of immunodeficiency diseases, including a positive HIV test result.
A positive Hepatitis B surface antigen (HBsAg), Hepatitis C or Syphilis test result.
Drug or alcohol abuse within the 12 months prior to dosing
Tuberculosis symptoms, complication of tuberculosis, contact with patients with suspected tuberculosis symptoms
Other protocol-defined inclusion/exclusion criteria may apply